Advertisement
Screener

Revolution Medicines, Inc. (RVMD) P/E Ratio

2.8 / 5 stars · 68/120 Roast Me

Revolution Medicines, Inc. PE Ratio

The price-to-earnings (P/E) ratio tells you how many dollars investors pay for each dollar of a company's annual profit. It is market capitalization divided by net income over the trailing four quarters, meaning the four most recent filed quarters added together, and the table shows both amounts. A higher P/E means investors are paying more for each dollar of current earnings, often because they expect profits to grow; a negative P/E means the company lost money over those four quarters. Each point uses the filed share count and the last closing price on or before that quarter-end date, never today's price.

  • Revolution Medicines, Inc. pe ratio for the quarter ending 2026-06-30 was -22.69, a change of -14.22 year-over-year.
  • Revolution Medicines, Inc. pe ratio for the quarter ending 2026-03-31 was -14.18, a change of -4.74 year-over-year.
  • Revolution Medicines, Inc. pe ratio for the quarter ending 2025-12-31 was -13.87, a change of -0.32 year-over-year.
  • Revolution Medicines, Inc. pe ratio for the quarter ending 2025-09-30 was -9.21, a change of 4.2 year-over-year.
  • Revolution Medicines, Inc. pe ratio for fiscal 2026 was -22.69.
  • Revolution Medicines, Inc. pe ratio for fiscal 2025 was -13.87, a change of -0.32 from fiscal 2024.
  • Revolution Medicines, Inc. pe ratio for fiscal 2024 was -13.55, a change of -2.73 from fiscal 2023.
  • Revolution Medicines, Inc. pe ratio for fiscal 2023 was -10.82, a change of -2.16 from fiscal 2022.
Available history
2020-03-31 to 2026-06-30
Data captured

Historical PE Ratio

DatePE RatioMarket capitalizationNet income 12 month
2026-06-30-22.69$40.12B-$1.77B
2026-03-31-14.18$19.45B-$1.37B
2025-12-31-13.87$15.69B-$1.13B
2025-09-30-9.21$8.85B-$960.98M
2025-06-30-8.47$6.88B-$812.06M
2025-03-31-9.44$6.59B-$697.51M
2024-12-31-13.55$8.13B-$600.09M
2024-09-30-13.42$7.61B-$567.06M
2024-06-30-12.38$6.43B-$519.21M
2024-03-31-10.98$5.32B-$484.27M
2023-12-31-10.82$4.72B-$436.37M
2023-09-30-9.14$3.03B-$331.34M
2023-06-30-9.86$2.92B-$296.23M
2023-03-31-8.88$2.3B-$259.16M
2022-12-31-8.66$2.15B-$248.71M
2022-09-30-7.07$1.73B-$244.87M
2022-06-30-6.46$1.45B-$224.49M
2022-03-31-9.12$1.89B-$207.56M
2021-12-31-9.97$1.87B-$187.09M
2021-09-30-12.02$2.03B-$168.62M
2021-06-30-16.34$2.34B-$142.9M
2021-03-31-26.78$3.37B-$125.82M
2020-12-31-24.38$2.64B-$108.16M
2020-09-30-26.07$2.31B-$88.55M
2020-06-30-25.13$1.86B-$74.15M
2020-03-31-22.66$1.29B-$57.05M

Annual PE Ratio

DatePE RatioMarket capitalizationNet income 12 month
2026-06-30-22.69$40.12B-$1.77B
2025-12-31-13.87$15.69B-$1.13B
2024-12-31-13.55$8.13B-$600.09M
2023-12-31-10.82$4.72B-$436.37M
2022-12-31-8.66$2.15B-$248.71M
2021-12-31-9.97$1.87B-$187.09M
2020-12-31-24.38$2.64B-$108.16M

Similar stocks

Stock NameCountryMarket CapPE Ratio
BIOGEN INC. (BIIB)United States$33.427B19.60
EXELIXIS, INC. (EXEL)United States$14.358B16.15
NEUROCRINE BIOSCIENCES INC (NBIX)United States$14.131B24.25
HALOZYME THERAPEUTICS, INC. (HALO)United States$13.083B21.59
Twist Bioscience Corp (TWST)United States$11.540B-47.21
BIO-TECHNE Corp (TECH)United States$11.379B74.68
REPLIGEN CORP (RGEN)United States$10.755B185.31
Krystal Biotech, Inc. (KRYS)United States$10.210B45.56
Kymera Therapeutics, Inc. (KYMR)United States$9.631B-31.69
ImmunityBio, Inc. (IBRX)United States$9.157B-9.29